Geode Capital Management
MTNB icon

Geode Capital Management’s Matinas BioPharma MTNB Stock Holding History

Geode Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.1K Sell
49,135
-16,035
-25% -$10.3K ﹤0.01% 4328
2026
Q1 		$32.6K Buy
65,170
+9,200
+16% +$5.76K ﹤0.01% 4395
2025
Q4 		$32.8K Hold
55,970
– – ﹤0.01% 4311
2025
Q3 		$106K Buy
55,970
+476
+0.9% +$684 ﹤0.01% 4119
2025
Q2 		$49.4K Buy
55,494
+8,753
+19% +$6.41K ﹤0.01% 4219
2025
Q1 		$24.3K Buy
46,741
+3,274
+8% +$1.94K ﹤0.01% 4314
2024
Q4 		$22.2K Sell
43,467
-3,262
-7% -$4.96K ﹤0.01% 4372
2024
Q3 		$165K Buy
46,729
+903
+2% +$5.75K ﹤0.01% 3964
2024
Q2 		$363K Buy
45,826
+3,117
+7% +$28.3K ﹤0.01% 3690
2024
Q1 		$579K Buy
42,709
+11,179
+35% +$133K ﹤0.01% 3557
2023
Q4 		$341K Sell
31,530
-7,680
-20% -$86.7K ﹤0.01% 3747
2023
Q3 		$255K Buy
39,210
+31
+0.1% +$381 ﹤0.01% 3881
2023
Q2 		$705K Buy
39,179
+3,082
+9% +$71.9K ﹤0.01% 3487
2023
Q1 		$848K Hold
36,097
– – ﹤0.01% 3418
2022
Q4 		$902K Buy
36,097
+2,293
+7% +$76.3K ﹤0.01% 3389
2022
Q3 		$1.07M Buy
33,804
+2,780
+9% +$109K ﹤0.01% 3357
2022
Q2 		$1.23M Sell
31,024
-1,590
-5% -$60.6K ﹤0.01% 3328
2022
Q1 		$1.31M Buy
32,614
+877
+3% +$32.3K ﹤0.01% 3487
2021
Q4 		$1.6M Buy
31,737
+3,842
+14% +$205K ﹤0.01% 3478
2021
Q3 		$1.81M Buy
27,895
+1,516
+6% +$65.4K ﹤0.01% 3396
2021
Q2 		$1.02M Buy
26,379
+1,061
+4% +$45.6K ﹤0.01% 3586
2021
Q1 		$1.33M Buy
25,318
+2,891
+13% +$194K ﹤0.01% 3441
2020
Q4 		$1.52M Buy
22,427
+839
+4% +$38.9K ﹤0.01% 3214
2020
Q3 		$826K Hold
21,588
– – ﹤0.01% 3278
2020
Q2 		$834K Hold
21,588
– – ﹤0.01% 3200
2020
Q1 		$647K Buy
21,588
+4,212
+24% +$254K ﹤0.01% 3191
2019
Q4 		$1.97M Buy
17,376
+1,282
+8% +$74.3K ﹤0.01% 3013
2019
Q3 		$507K Buy
16,094
+2,447
+18% +$88.4K ﹤0.01% 3468
2019
Q2 		$584K Hold
13,647
– – ﹤0.01% 3409
2019
Q1 		$743K Buy
13,647
+5,512
+68% +$297K ﹤0.01% 3282
2018
Q4 		$242K Hold
8,135
– – ﹤0.01% 3616
2018
Q3 		$374K Sell
8,135
-37
-0.5% -$795 ﹤0.01% 3565
2018
Q2 		$177K Sell
8,172
-2,704
-25% -$78.1K ﹤0.01% 3753
2018
Q1 		$415K Buy
10,876
+292
+3% +$15.4K ﹤0.01% 3463
2017
Q4 		$613K Buy
10,584
+553
+6% +$35.6K ﹤0.01% 3283
2017
Q3 		$662K Buy
10,031
+127
+1% +$8.48K ﹤0.01% 3267
2017
Q2 		$836K Buy
+9,904
New +$1.33M ﹤0.01% 3172

Other funds holding MTNB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management's MTNB Position: Q2 2026 in Review

Geode Capital Management reduced its Matinas BioPharma (MTNB) stake by 25% in Q2 2026, selling an estimated $10.3K and leaving 49,135 shares worth $30.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4328.

Geode Capital Management first reported a position in MTNB in Q2 2017 and has held it in 37 quarters since. The position peaked at $1.97M in Q4 2019. 19 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • Geode Capital Management held 49,135 shares of Matinas BioPharma worth $30.1K as of Q2 2026.
  • Geode Capital Management sold 16,035 Matinas BioPharma shares in Q2 2026, an estimated $10.3K.
  • Matinas BioPharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4328 holding.
  • Geode Capital Management first reported a position in Matinas BioPharma in Q2 2017 and has held it in 37 quarters since.
  • Geode Capital Management's Matinas BioPharma position peaked at $1.97M in Q4 2019.
  • 19 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.